vimarsana.com

Page 34 - சீன கலைக்கழகம் ஆஃப் மருத்துவ அறிவியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Shenzhen proton therapy treatment center selects C-RAD Catalyst™ system

Share this article STOCKHOLM, Dec. 23, 2020 /PRNewswire/ C-RAD has now received the purchase order from the Belgium company Ion Beam Applications SA (IBA), regarding the supply of C-RAD s surface tracking solution for Shenzhen proton therapy center. The purchase order includes multiple Catalyst™ systems and a Sentinel™  4DCT system including a multiyear service agreement. In June 2020 C-RAD and IBA signed a letter of Intent for the supply of the Catalyst and Sentinel systems for this project. Since June C-RAD and IBA worked on the supplier evaluation process. The successful finalization was a pre-requisite for the purchase agreement. Shenzhen Tumor Hospital is a member of the Chinese Academy of Medical Sciences (CAMS). CAMS is a leading health network for cancer prevention and treatment in China, which is active in cancer research, comprehensive education and research-based prevention. C-RAD has already a Catalyst installation with a photon treatment system at the CAMS

Chinese medical school launches recruitment programme

Chinese medical school launches recruitment programme Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing says it is looking for 100 postdoctoral researchers and professors Search for new talent comes at the end of Donald Trump’s US presidency, a period marked by strained relations between scientific communities in China and America

CASI Pharmaceuticals Announces CNCT19 (CD19 CAR-T) Receives China Breakthrough Therapy Designation

Share this article Share this article ROCKVILLE, Md., and BEIJING, Dec. 23, 2020 /PRNewswire/  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that the Chinese Center for Drug Evaluation, a division of the China National Medical Products Association, has granted Breakthrough Therapy Designation ( Breakthrough Designation ) to its partner Juventas Cell Therapy Ltd. for CNCT19, a potential CD19 CAR-T therapy for the treatment of adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). CASI has co-commercial rights to CNCT19 and is a shareholder of Juventas. The Breakthrough Designation for CNCT19 was granted based on initial data from the ongoing single arm, open-label, non-randomized, dose-escalation, Phase I study designed to determine the safety and efficacy of CNCT19 in B-ALL.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.